Results 1 to 10 of about 389,134 (209)

COMMUNITY STRUCTURE IN JAZZ

open access: yesInternational Journal of Modeling, Simulation, and Scientific Computing, 2003
Using a database of jazz recordings we study the collaboration network of jazz musicians. We define the network at two different levels. First we study the collaboration network between individuals, where two musicians are connected if they have played ...
Leon Danon
exaly   +3 more sources

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro

open access: yesScientific Reports, 2023
Liposomal formulations are hypothesized to alleviate anthracycline cardiotoxicity, although this has only been documented clinically for doxorubicin.
Marie C. Fortin   +5 more
doaj   +1 more source

Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies

open access: yesClinical and Translational Science, 2021
American Academy of Sleep Medicine practice parameters designate sodium oxybate (SXB) as a standard of care for cataplexy, excessive daytime sleepiness (EDS), and disrupted night‐time sleep in narcolepsy.
Cuiping Chen   +3 more
doaj   +1 more source

Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary

open access: yesNeurology and Therapy, 2023
Narcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem®), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolepsy.
Russell Rosenberg   +5 more
doaj   +1 more source

Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia

open access: yesClinical and Translational Science, 2023
JZP458 is a recombinant Erwinia chrysanthemi asparaginase for patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who have developed hypersensitivity to Escherichia coli–derived asparaginases. A population pharmacokinetic (PopPK)
Tong Lin   +5 more
doaj   +1 more source

A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers

open access: yesClinical and Translational Science, 2021
L‐asparaginase has been an important component of acute lymphoblastic leukemia (ALL) therapy for over 40 years, and is standard therapy during ALL induction and consolidation treatment.
Tong Lin   +6 more
doaj   +1 more source

Examining the impact of excessive daytime sleepiness on utility scores in patients with obstructive sleep apnoea and/or narcolepsy in five European countries

open access: yesBMC Neurology, 2022
Background Excessive daytime sleepiness (EDS) is a cardinal symptom of narcolepsy and affects many patients with obstructive sleep apnoea (OSA). EDS is associated with reduced quality of life, increased accident risk, and poor workplace performance ...
M. Janelle Cambron-Mellott   +4 more
doaj   +1 more source

Shared decision-making and the caregiver experience in tuberous sclerosis complex: results from a UK survey

open access: yesOrphanet Journal of Rare Diseases, 2023
Background Tuberous sclerosis complex (TSC) is a rare genetic condition commonly accompanied by neurological and neuropsychological disorders, resulting in a high burden of illness for individuals and a substantial impact on their caregivers.
Hanna Skrobanski   +7 more
doaj   +1 more source

Understanding the burden of illness of excessive daytime sleepiness associated with obstructive sleep apnea: a qualitative study

open access: yesHealth and Quality of Life Outcomes, 2020
Background Obstructive sleep apnea (OSA) is associated with excessive daytime sleepiness (EDS), which may go undiagnosed and can significantly impair a patient’s health-related quality of life (HRQOL).
Laura Tesler Waldman   +5 more
doaj   +1 more source

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer

open access: yesJournal of Comparative Effectiveness Research, 2023
Aim: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. Methods: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a ...
Raj Hanvesakul   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy